Azitra Q1 2024 net loss $2.9M; cash $3.0M; ATR-12/ATR-04 clinical updates

Azitra, Inc.

2024-Q1 EPS reported -$0.15

Q1 2024 net loss $2.9M vs $2.5M YoY; R&D and G&A each $1.5M vs $0.8M prior year.
Cash and cash equivalents $3.0M as of 3/31/2024; raised $5.0M in Feb 2024 follow-on offering.
ATR-12 Phase 1b trial activated sites, initial patients identified; safety data expected late 2024.
ATR-04 pre-IND meeting completed; IND submission planned mid-2024 for Phase 1b in EGFRi rash.
Bayer joint development agreement progresses; licensing agreement with upfront payment under discussion.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Azitra, Inc. reported the quarter ended March 31, 2024 results: revenue $0, net income $2.9 million.

Period: the quarter ended March 31, 2024
Revenue: $0
Net income: $2.9 million
Result: reported results

Exact text from the filing

Financial Results for the Year Ended December 31, 2023 ● Service Revenue – Related Party : The Company generated $0 service revenue during the quarter ended March 31, 2024, compared to $113,300 for the comparable period in 2023. ● Research and Development (R&D) expenses : R&D expenses for the quarter ended March 31, 2024, were $1.5 million compared to $0.8 million for the comparable period in 2023. ● General and Administrative (G&A) expenses : G&A expenses for the quarter ended March 31, 2024, were $1.5 million compared to $0.8 million for the comparable period in 2023. ● Net Loss was $2.9 million for the quarter ended March 31, 2024, compared to $2.5 million for the comparable period in 2023. ● Cash and cash equivalents : As of March 31, 2024, the Company had cash and cash equivalents of $3.0 million.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Azitra, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-018497

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.